Patent ID: 9695397
Date: 2017-07-04
CPC Classifications: A61K,A61P,C12N,Y02A

Claim:
1. A method of treating an individual susceptible to cancer, the method comprising: developing an anti-alloantigen immunity in the individual prophylactically, prior to onset of the cancer by administering to the individual a priming composition comprising allogeneic activated Th1 memory cells and cross-linking agents for cross-linking the CD3 and CD28 surface moieties on the Th1 memory cells, wherein the Th1 memory cells are activated by the cross-linking of the CD3 and CD28 surface molecules at the time of administration, wherein administration of the priming composition causes increased Th1 anti-alloantigen specific titer in circulation, wherein the anti-alloantigen immunity is developed in the individual prior to administration of cancer related antigens; and administering an activating composition comprising allogeneic activated Th1 memory cells and one or more cancer-related antigens to the primed individual, wherein the activating composition is administered after the onset of cancer in the individual.